Dr. Josep Antoni Grífols i Roig sets up Instituto Central de Análisis Clínicos, Bacteriológicos y Químicos in Barcelona, prior to Laboratorios Grifols.
Dr. Grífols i Roig, and his sons Josep Antoni and Víctor Grífols i Lucas, establish Laboratorios Grifols in Barcelona, a company specialized in clinical analyses and the preparation of lyophilized plasma.
Production of the first single-donor lyophilized plasma in continental Europe. Grifols patents this process in Spain and develops a lyophilizer and complementary devices to later inject plasma as a therapy.
Grifols opens the first private blood bank in Spain.
Dr. Josep Antoni Grífols Lucas develops the plasmapheresis technique.
First plasma fractionation plant in Spain begins operations.
Grifols opens its new production facility in Barcelona.
Dr. Víctor Grífols i Lucas lead Grifols to become the first non-U.S. company to obtain a FDA establishment license and a FDA license for a biological product (albumin).
Grifols acquires the U.S.-based company SeraCare, currently Biomat USA, along with its 43 donors centers.
Grifols acquires the assets of Alpha Therapeutic Corporation-Mitsubishi, including its plasma therapy manufacturing plant in Los Angeles, California.
FDA grants approval for immunoglobulin Barcelona plant (IVIG).
Grifols is listed on the Spanish stock exchange.
Grifols acquires Talecris Biotherapeutics to become the third-largest global manufacturer of plasma-derived protein therapies.
Grifols is listed on the NASDAQ stock exchange.
Acquisition of the transfusional diagnostic assets from Novartis.
Acquisition of Hologic’s share of NAT donor screening unit.
Latest findings released from the AMBAR clinical trial, which demonstrate the positive impact of the protocol in slowing down disease progression in patients with mild to moderate Alzheimer’s.
Strategic alliance with Shanghai RAAS in China